Professor Dyfrig Hughes

Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil

  1. 2008
  2. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  3. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  4. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  5. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  6. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  7. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  8. Published
  9. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  10. Published
  11. Published
  12. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  13. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  14. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  15. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  16. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  17. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  18. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  19. Published

    Charitable contributions to funding cancer services for children and young people in England and Wales

    Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Jan 2008, In: Journal of Child Health Care. 12, 2, p. 156-168

    Research output: Contribution to journalArticlepeer-review

  20. Published

    Chiral chromatography: Costs of chiral switching.

    Hughes, D. & Hughes, D. A., 1 Jan 2008, In: Pharmaceutical Journal. 281, p. 213

    Research output: Contribution to journalArticlepeer-review

  21. Published

    Cost-effectiveness considerations in pharmacogenetics.

    Hughes, D. & Hughes, D. A., 1 Jan 2008.

    Research output: Contribution to conferencePaper

  22. Published

    Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

    Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  23. Published

    Effects of the abolition of prescription charges in Wales: a preliminary analysis.

    Hughes, D., Cohen, D., Alam, M. F., Hughes, D. A., Dunstan, F. & Routledge, P., 1 Jan 2008, In: International Journal of Pharmacy Practice. 16, Supplement 1, p. A39

    Research output: Contribution to journalArticlepeer-review

  24. Published

    Integrating compliance and persistence in health economics models

    Hughes, D. & Hughes, D. A., 1 Jan 2008.

    Research output: Contribution to conferencePaper

  25. Published

    Investigating factors influencing user choices to visit either general practioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment.

    Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  26. Published

    Public health interventions to promote well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness.

    Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T., Morgan, R., Woods, R. T., Burholt, V., Edwards, R. T., Reeves, C. & Yeo, S. T., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  27. Published

    Public health interventions to promote well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness: Evidence Tables.

    Hughes, D., Linck, P. G., Windle, G., Linck, P., Morgan, R., Hughes, D. A., Burholt, V., Reeves, C., Yeo, S. T., Woods, R. T., Edwards, R. T. & Russell, I. T., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  28. Published

    Understanding medication compliance and persistence from an economics perspective

    Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Jan 2008, In: Value in Health. 11, 4, p. 600-610

    Research output: Contribution to journalArticlepeer-review

  29. Published

    Economic considerations for market access of new health technologies: A case study of pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Feb 2008.

    Research output: Contribution to conferencePaper

  30. Published

    From efficacy to cost-effectiveness: Impact of patient compliance

    Hughes, D. & Hughes, D. A., 1 Feb 2008.

    Research output: Contribution to conferencePaper

  31. Published
  32. Published

    Statistical comments are unfounded.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Mar 2008, In: Value in Health. 11, 2, p. 346

    Research output: Contribution to journalArticlepeer-review

  33. Published

    The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data

    Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Mar 2008.

    Research output: Contribution to conferencePaper

  34. Published

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Apr 2008.

    Research output: Contribution to conferencePaper

  35. Published

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Apr 2008.

    Research output: Contribution to conferencePaper

  36. Published

    Effects of the abolition of prescription charges in Wales: A preliminary analysis

    Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Apr 2008.

    Research output: Contribution to conferencePaper

  37. Published

    Costs of non-compliance to antipsychotic medications among patients with schizophrenia.

    Hughes, D., Hughes, D. A., Salas, M., Zuluaga, A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 May 2008.

    Research output: Contribution to conferencePaper

  38. Published

    The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 May 2008.

    Research output: Contribution to conferencePaper

  39. Published

    Economic considerations for pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Jun 2008.

    Research output: Contribution to conferencePaper

  40. Published

    Medicines concordance and game theory.

    Hughes, D. & Hughes, D. A., 1 Oct 2008, In: British Journal of Clinical Pharmacology. 66, 4, p. 577

    Research output: Contribution to journalArticlepeer-review

  41. Published

    Impact of the abolition of the prescription charge in Wales

    Hughes, D. & Hughes, D. A., 1 Nov 2008.

    Research output: Contribution to conferencePaper

  42. Published

    Methodological Issues in the literature on costs of non-compliance in chronic diseases.

    Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Nov 2008, In: Value in Health. 11, 6, p. A571-A572

    Research output: Contribution to journalArticlepeer-review

  43. Published

    Methodological issues in the literature on costs of non-compliance in chronic diseases

    Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Nov 2008.

    Research output: Contribution to conferencePaper

  44. Published

    The all wales medicines strategy group: assessments and appraisals

    Hughes, D. & Hughes, D. A., 1 Nov 2008.

    Research output: Contribution to conferencePaper

  45. Published

    Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens

    Hughes, D. & Hughes, D. A., 1 Dec 2008, In: British Journal of Clinical Pharmacology. 65, 6, p. 871-878

    Research output: Contribution to journalArticlepeer-review

  46. 2009
  47. Published

    A systematic review and empirical analysis of the relation between dose and duration of drug action.

    Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Jan 2009, p. TP40.

    Research output: Contribution to conferencePaper

  48. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/ReportCommissioned report

  49. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/ReportCommissioned report

  50. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/ReportCommissioned report

  51. Published
  52. Published

    Assessment, Determinants & Economics of Medication Compliance & Persistence Forum.

    Hughes, D., Hughes, D. A., Gwadry-Sridhar, F. & Manias, E., 1 Jan 2009.

    Research output: Contribution to conferencePaper